Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

BMY-JNJ collaboration could be bad for PTLA, if

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 721
Posts 108,625
Boards Moderated 21
Alias Born 09/05/02
160x600 placeholder
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 PR Newswire (US) - 7/17/2019 8:30:00 AM
Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) ... PR Newswire (US) - 7/8/2019 8:30:00 AM
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re... PR Newswire (US) - 6/19/2019 11:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:43:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:37:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:34:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:27:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:16:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:49:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 5:07:23 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire Inc. - 5/28/2019 4:30:00 PM
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® i... GlobeNewswire Inc. - 5/22/2019 10:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 8:38:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 8:07:58 AM
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/8/2019 8:01:00 AM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/25/2019 11:21:27 AM
Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Developm... GlobeNewswire Inc. - 4/24/2019 8:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/22/2019 6:03:30 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/22/2019 6:03:24 AM
Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 GlobeNewswire Inc. - 4/17/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:45:27 PM
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust,... GlobeNewswire Inc. - 4/10/2019 8:30:00 AM
DewDiligence Member Level  Monday, 04/16/18 05:03:43 PM
Re: None
Post # of 178 
BMY-JNJ collaboration could be bad for PTLA, if FXIa inhibition usurps FXa inhibition as the preferred MoA for anticoagulation:

#msg-140083631

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist